For the first time, a pharmacotherapy for overweight and obesity has reduced cardiovascular events in patients with established cardiovascular disease in the absence of type 2 diabetes.Read More
This brief review shares a pragmatic road map for managing atherosclerosis in patients who cannot or will not take a statin. And it looks ahead to new statin alternatives on the horizon.
Five prior attempts to gain U.S. regulatory approval for nonprescription access to statin therapy have failed. A novel technology-assisted approach is showing promise where past efforts came up short.
For the first time, the gut microbe-dependent metabolite TMAO has been shown to predict incident coronary artery disease in a large prospective population study of apparently healthy adults.
A deeper dive into the large randomized trial finds no benefit with even the highest blood levels of EPA, casting further doubt on the results of the REDUCE-IT trial and a risk-reducing role for fish oil.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Nuance is needed when considering how dietary carbohydrate intake impacts metabolism and clinical outcomes, a new review paper concludes.
We share our experience providing safe and routine access to phase II cardiac rehabilitation to patients across nine regional cardiac rehab centers using inclusive telemedicine methods and resourceful center-based care.